Stockscreener 앱 받기
3.18
3.34%
-0.11
시장 영업 전:
3.19
0.010
+0.31%
Recursion Pharmaceuticals Inc 주식(RXRX)의 최신 뉴스
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed (RXRX) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI-Driven Drug Discovery Advances - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX: AI-driven platform advances multiple clinical programs with major data readouts expected soon - TradingView
Recursion Pharmaceuticals (RXRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Here’s Why Recursion Pharmaceuticals (RXRX) is Among the Best Penny Stocks - Insider Monkey
Recursion Pharmaceuticals Stock Surges After Consecutive Losses - asatunews.co.id
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceutica - GuruFocus
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock - Investing.com UK
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade - Stock Titan
Recursion Q1 2026 slides: pipeline advances amid revenue shortfall - Investing.com
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Najat Khan plans Rule 144 sale of Recursion (NASDAQ: RXRX) shares on 05/15/2026 - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway - Sahm
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Gibson files Form 144 to sell 40,000 Class A shares (RXRX) - Stock Titan
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bumpus Namandje - Moomoo
Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business Updates - Insider Monkey
9 Stocks Crushing the Market With Surging Returns - Insider Monkey
Insider Sell: Namandje Bumpus Sells Shares of Recursion Pharmace - GuruFocus
10 Best Penny Stocks with Huge Upside Potential - Insider Monkey
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Recursion (NASDAQ: RXRX) director sells 30,000 shares under 10b5-1 plan - Stock Titan
RXRX Stock Grinds Higher As Earnings Beat Supports AI Drug Story - timothysykes.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Proof and AI Platform Advancements - Quiver Quantitative
RXRX Stock Climbs As Earnings Beat Highlights AI Drug Progress - StocksToTrade
Recursion Stock Jumps Before Goldman Sachs Event as AI-Drug Trade Gets Fresh Heat - TechStock²
RXRX Stock Climbs As Earnings Beat Extends Cash Runway - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results - Yahoo Finance
Earnings call transcript: Recursion Pharmaceuticals Q1 2026 results show EPS beat but revenue miss - Investing.com
Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation - Yahoo Finance
[144] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - MSN
Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026 - Investing.com Nigeria
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals to present at Goldman Sachs Healthcare Conference on June 9, 2026 - Pluang
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum - simplywall.st
RXRX (NASDAQ) affiliate sales reported: Borgeson sells 230,000 shares in 2026 - Stock Titan
Recursion to Participate in Upcoming Investor Conferences - marketscreener.com
Clinical-stage TechBio Recursion to appear at Goldman Sachs healthcare event - Stock Titan
RXRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
1.27%
1.43%
자본화:
|
볼륨(24시간):